Online testosterone therapy has become a mainstream service. A man can order a blood kit, talk to a clinician by video, and have testosterone shipped home. Hone Health, which treats testosterone and other hormone problems online, raised $228 million in November 2026 and says it has treated more than 200,000 patients.[1] Hims & Hers added injectable and oral testosterone in October 2026. The company says testosterone grew faster than any category outside weight loss in its first three quarters.[3]
This article is general information, not medical advice. NextMD is a directory of physician-led practices. We do not diagnose, treat, or recommend any treatment. Whether testosterone therapy is right for you is a decision to make with a licensed physician who knows your full medical history.
Online programs make testosterone care easy to start. Medical guidelines ask for more than a single lab result before treatment begins. Here is what the guidelines say, where online and in-person care differ, and what to ask before you start either way.
How online testosterone programs work
The two companies in the news this month follow a similar pattern.
Hone Health charges $65 for a panel of 70 biomarkers and a clinician consult. Patients who start treatment pay $150 a month plus the cost of medications.[2] Hone requires bloodwork every 90 days and a conversation with a physician before refills. Members can message their clinician between visits.[2]
Hims & Hers starts with an online medical intake. Customers collect a small blood sample at home with a push-button device worn on the upper arm. Hims says the sample is tested for 22 biomarkers, including total and free testosterone.[3] A licensed provider reviews the results in a live visit. Treatment options include injectable testosterone, an FDA-approved oral testosterone, and a compounded product.[3] Hims notes that compounded drugs are not approved or evaluated by the FDA for safety, effectiveness, or quality.[3]
Both companies describe follow-up labs and ongoing clinician access. Neither includes an in-person physical exam in the materials we reviewed.
What the medical guidelines ask for
Three professional sources set out how low testosterone should be diagnosed and treated.
Symptoms and lab results must both point the same way. The American Urological Association (AUA) says a man is a candidate for therapy only when he has low testosterone levels together with symptoms or signs linked to it.[7] The AUA adds that those symptoms are non-specific. Tiredness, stress, and depression can cause the same complaints.[7]
One test is not enough. The Endocrine Society's 2026 statement says diagnosis should rest on at least two early-morning, fasting testosterone tests. It cites a common clinical threshold near 300 ng/dL.[4] The Society's guideline recommends repeating the morning fasting measurement to confirm the result.[5]
Lab quality matters. The Society warns that testosterone assays are not standardized. The same blood sample can read "low" at one lab and "normal" at another.[4] It recommends assays certified by the Centers for Disease Control and Prevention (CDC) Hormone Standardization (HoST) program.[4]
Other causes come first. Obesity and medicines such as corticosteroids or opioids can lower testosterone. The Society says clinicians should rule out reversible causes before treating.[4] For men with a body mass index (BMI) above 27 and no other cause found, it calls weight loss the usual first step.[4]
Some men should not start without more evaluation. The Endocrine Society guideline recommends against starting testosterone in men who:[5]
Plan to father a child soon
Have breast or prostate cancer, or a prostate nodule
Have a prostate-specific antigen (PSA) level above 4 ng/mL, or above 3 ng/mL with higher prostate cancer risk, without a urology evaluation
Have an elevated hematocrit (the share of blood made up of red cells)
Have untreated severe obstructive sleep apnea
Had a heart attack or stroke in the past six months
Monitoring continues after treatment starts. The guideline calls for a standard plan during the first year. It covers symptoms and side effects, testosterone and hematocrit levels, and prostate cancer risk.[5]
What the FDA changed in 2025, and what it proposed in 2026
On February 28, 2025, the FDA told makers of testosterone products to remove the boxed warning language about increased cardiovascular risk.[6] The change followed the TRAVERSE trial, which concluded there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for low testosterone.[6]
The same action added a new warning. Blood pressure studies showed that testosterone products raise blood pressure across the class. Products without that warning now must carry one.[6] In 2025 the FDA also kept the "Limitation of Use" language for age-related low testosterone.[6]
The Endocrine Society notes other findings from TRAVERSE. Treated men had roughly a 50% relative increase in pulmonary embolism, a blood clot in the lungs, and more bone fractures.[4] Long-term safety, including for prostate cancer, has not been established.[4]
June 2026: proposed label changes. On June 18, 2026, the Department of Health and Human Services (HHS), through the FDA, asked makers of testosterone products to update their labels.[8] The requested changes would:
Remove the limitation of use that says safety and effectiveness have not been established in men with age-related low testosterone.[8]
Narrow the prostate cancer contraindication. Current labels generally say testosterone should not be used with known or suspected prostate cancer. Under the request, it would be contraindicated only in men with metastatic prostate cancer.[8]
Revise the warning about an enlarged prostate (benign prostatic hyperplasia). The FDA found no worsening of symptoms in men with mild to moderate disease, with less evidence for severe symptoms.[8]
HHS describes these as requested, proposed changes.[8] The proposed labeling still recommends that clinicians assess prostate cancer risk, screen before treatment, and monitor during therapy.[8] We found no FDA announcement that the new labels have been finalized as of November 21, 2026. The label on a given product may still carry the older wording.
April 2026: a possible new use. The FDA invited makers of approved testosterone products to discuss seeking a new indication: low libido in men with low testosterone and no known cause.[9] Approved testosterone products are currently indicated only for low testosterone tied to known structural or genetic causes.[9] Any new indication would still need approval.[9]
Labels and guidelines are separate documents. The Endocrine Society's 2018 guideline cautions against starting testosterone in men with prostate cancer or a prostate nodule.[5] Ask your physician how they apply both.
What an in-person physician adds
An online program can follow the guideline steps above. Some parts of the evaluation are easier in an exam room.
A physical exam. The guideline's cautions include a prostate nodule.[5] Finding one requires an examination.
Blood pressure readings over time. The FDA's new warning makes blood pressure part of monitoring.[6] A physician who sees you regularly can track it against your baseline.
A search for other causes. Sleep apnea, weight, and medications all affect testosterone.[4][5] A physician who manages your other conditions already knows about them.
One record. Hematocrit, PSA, blood pressure, and lipids are tracked in the same chart as everything else.
Time is the limit in many traditional offices. The average primary care visit is short, as we covered in why your primary doctor only spends seven minutes with you. Concierge and direct primary care practices keep smaller patient panels. That allows longer visits for a conversation that covers symptoms, other causes, and family plans.
Video visits still have a place. Our guide to telehealth vs in-person primary care covers when a video visit is enough.
Questions to ask before you start, online or in person
How many tests confirm my level? Ask whether you will have at least two early-morning, fasting results.[4]
Which lab runs the test? Ask whether the assay is CDC HoST certified.[4]
What else could explain my symptoms? Ask what was checked: weight, sleep, medications, mood.[4]
Do I want children soon? Raise it before any prescription.[5]
What is my PSA and hematocrit before treatment? Ask for the baseline numbers.[5]
What is monitored, and how often? Testosterone, hematocrit, prostate risk, and blood pressure all belong on the plan.[5][6]
Is the drug FDA-approved or compounded? Ask the program to name it.[3]
Who sees my full record? If an online program treats you, decide how your primary care physician will receive the results.
Hormone products sold online are expanding beyond testosterone. Our explainer on what sermorelin, NAD+, and glutathione actually are covers the peptides Hims began selling in 2026.
Finding a physician who can take the time
Many concierge and direct primary care practices are led by internal medicine and family physicians who manage hormone questions alongside the rest of a patient's care. Ask any practice how it evaluates low testosterone before you join.
FAQ
Can I get testosterone therapy online?
Yes. Companies such as Hone Health and Hims & Hers prescribe testosterone after an online intake, home or lab blood testing, and a video visit with a licensed clinician.[2][3] Availability varies by state.
What testosterone level counts as low?
The Endocrine Society cites a common clinical threshold near 300 ng/dL, based on at least two early-morning, fasting tests.[4] A low number alone does not establish a diagnosis. Symptoms must also be present.[7]
Are at-home testosterone tests accurate?
The Endocrine Society says testosterone testing is often inaccurate because assays are not standardized.[4] It recommends CDC-certified assays. Ask your program which lab and assay it uses.
Did the FDA say testosterone is safe for the heart?
In 2025 the FDA removed boxed warning language about increased cardiovascular risk after the TRAVERSE trial. It also added a class-wide warning about increased blood pressure.[6] Long-term safety, including for prostate cancer, has not been established.[4]
Is testosterone now FDA-approved for age-related low testosterone?
Not as of November 21, 2026, based on what we found. In June 2026 HHS asked manufacturers to remove the label language saying safety and effectiveness are not established for age-related low testosterone.[8] Removing that limitation is different from approving a new use. Approved products remain indicated for low testosterone with known structural or genetic causes.[9]
Does testosterone therapy affect fertility?
The Endocrine Society guideline recommends against starting testosterone in men planning to father a child in the near term.[5] Discuss family plans with a physician before treatment.
Is online testosterone therapy cheaper than a concierge doctor?
Hone charges $150 a month plus medications.[2] Concierge and direct primary care fees cover all of your primary care, so the comparison depends on what else you need. Compare total yearly cost, including labs and medications.
A Note From the Author
I am not a doctor. This article provides general information and does not offer medical advice, diagnosis, or treatment. NextMD does not endorse any testosterone product, program, or company mentioned here. Talk with a licensed physician who knows your medical history before starting, stopping, or changing any medication. If you have chest pain, shortness of breath, or sudden swelling in one leg, call 911.
Looking for a physician who has time for these conversations? Search concierge and direct primary care practices on NextMD.
Sources
Hone Health. (2026, November 18). Hone Health Raises $228M to Expand Physician-Led Longevity Care for Men and Women. PR Newswire. Hone Health financing announcement.
Gliadkovskaya, A. (2026, November 18). Longevity platform Hone Health nabs $228M to build out offerings. Fierce Healthcare. Read on Fierce Healthcare.
Hims & Hers Health. (2026, October 21). Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men's Health Launch to Date. Business Wire. Hims testosterone launch announcement.
Endocrine Society. (2026, July 16). Statement on Testosterone Replacement Therapy. Endocrine Society statement.
Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. Find on PubMed.
U.S. Food and Drug Administration. (2025, February 28). FDA issues class-wide labeling changes for testosterone products. FDA labeling change notice.
American Urological Association. (2018; reviewed and validity confirmed 2024). Evaluation and Management of Testosterone Deficiency. AUA testosterone deficiency guideline summary.
U.S. Department of Health and Human Services. (2026, June 18). HHS Announces Requested Updates to Testosterone Therapy Product Labels. HHS press release.
U.S. Food and Drug Administration. (2026, April 16). FDA Takes Step Forward on Testosterone Therapy for Men. FDA press announcement.

